Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Notes Payables (2022 - 2023)

TriSalus Life Sciences' Notes Payables history spans 2 years, with the latest figure at $1.6 million for Q2 2023.

  • For Q2 2023, Notes Payables rose 66.65% year-over-year to $1.6 million; the TTM value through Jun 2023 reached $1.6 million, up 66.65%, while the annual FY2022 figure was $944000.0, N/A changed from the prior year.
  • Notes Payables reached $1.6 million in Q2 2023 per TLSIW's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.6 million in Q2 2023 to a low of $809000.0 in Q1 2022.